Standout Papers

Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein 2003 2026 2010 2018 1.1k
  1. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein (2003)
    Elizabeta Nemeth, Erika V. Valore et al. Blood
  2. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia (2022)
    Naval Daver, Alexander E. Perl et al. Journal of Clinical Oncology

Immediate Impact

14 by Nobel laureates 17 from Science/Nature 73 standout
Sub-graph 1 of 15

Citing Papers

Acute myeloid leukaemia
2023 Standout
T-cell-engaging bispecific antibodies in cancer
2023 Standout
2 intermediate papers

Works of Gary J. Schiller being referenced

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
2021
Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors
2018
and 2 more

Author Peers

Author Last Decade Papers Cites
Gary J. Schiller 6089 2358 2213 3241 374 10.0k
A. V. Hoffbrand 4607 1360 4084 2140 268 10.1k
Ernst Holler 9098 3020 1718 3014 366 16.2k
Judith E. Karp 5023 4536 1608 6174 272 14.0k
Tapani Ruutu 6670 2092 2282 1383 219 10.0k
Rüdiger Hehlmann 7690 1165 6314 2127 279 11.2k
Takanori Teshima 5436 2423 975 1783 478 10.3k
Nelson J. Chao 5307 2720 1649 2017 336 10.8k
E. Donnall Thomas 9679 3726 2135 1101 232 15.0k
Emanuele Angelucci 5063 1005 4366 779 304 8.1k
Ibrahim Yakoub‐Agha 4609 2691 1098 1346 402 7.3k

All Works

Loading papers...

Rankless by CCL
2026